Literature DB >> 23943105

Operative management of cholangiocarcinoma.

Ser Yee Lee1, Daniel Cherqui.   

Abstract

Cholangiocarcinomas (CCAs) are rare malignancies that originate from the epithelial cells of the bile ducts. It is the second most-common primary liver cancer after hepatocellular carcinoma. Recent epidemiologic studies have shown that the overall incidence and mortality rates of CCAs are increasing. Diagnosis is often challenging due to the difficulty in getting tissue/cytology for confirmation, and it comprises a combination of cross-imaging, tumor markers, histology, and cholangiography. Surgery involving major resections of liver, bile duct, pancreas, and at times adjacent vessels is the only chance for cure. Evaluation should be focused on the assessment of tumor resectability, hepatic reserve, and patient physiological fitness for major surgery. In patients not fit for major surgery, biliary drainage for jaundice is an appropriate intervention and if there is histologic confirmation of a CCA, palliative therapies focused on local and systemic disease control should be considered. The endeavor to expand the indications for liver transplantation reflects the efforts to provide an effective form of therapy for a previously untreatable disease. A multidisciplinary specialized approach should be the platform for providing the best comprehensive care for these patients. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2013        PMID: 23943105     DOI: 10.1055/s-0033-1351784

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  7 in total

1.  Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma.

Authors:  Angela Y Jia; Jian-Xiong Wu; Yu-Ting Zhao; Ye-Xiong Li; Zhi Wang; Wei-Qi Rong; Li-Ming Wang; Jing Jin; Shu-Lian Wang; Yong-Wen Song; Yue-Ping Liu; Hua Ren; Hui Fang; Wen-Qing Wang; Xin-Fan Liu; Zi-Hao Yu; Wei-Hu Wang
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 2.  Liver transplantation in the management of perihilar cholangiocarcinoma.

Authors:  Aliya F Gulamhusein; William Sanchez
Journal:  Hepat Oncol       Date:  2015-11-06

Review 3.  Liver transplantation for malignancies.

Authors:  Bijan Eghtesad; Federico Aucejo
Journal:  J Gastrointest Cancer       Date:  2014-09

4.  Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.

Authors:  Jingxiao Wang; Haichuan Wang; Michele Peters; Ning Ding; Silvia Ribback; Kirsten Utpatel; Antonio Cigliano; Frank Dombrowski; Meng Xu; Xinyan Chen; Xinhua Song; Li Che; Matthias Evert; Antonio Cossu; John Gordan; Yong Zeng; Xin Chen; Diego F Calvisi
Journal:  J Hepatol       Date:  2019-06-11       Impact factor: 25.083

Review 5.  Diagnostic-therapeutic management of bile duct cancer.

Authors:  José María Huguet; Miriam Lobo; José Mir Labrador; Carlos Boix; Cecilia Albert; Luis Ferrer-Barceló; Ana B Durá; Patricia Suárez; Isabel Iranzo; Mireia Gil-Raga; Celia Baez de Burgos; Javier Sempere
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

6.  BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways.

Authors:  Chen Yu Jiao; Qin Chao Feng; Chang Xian Li; Dong Wang; Sheng Han; Yao Dong Zhang; Wang Jie Jiang; Jiang Chang; Xuehao Wang; Xiang Cheng Li
Journal:  Cell Death Dis       Date:  2021-01-11       Impact factor: 8.469

7.  Curcumol Exerts Anticancer Effect in Cholangiocarcinoma Cells via Down-Regulating CDKL3.

Authors:  Jinduo Zhang; Gang Su; Zengwei Tang; Li Wang; Wenkang Fu; Sheng Zhao; Yongjiang Ba; Bing Bai; Ping Yue; Yanyan Lin; Zhongtian Bai; Jinjing Hu; Wenbo Meng; Liang Qiao; Xun Li; Xiaodong Xie
Journal:  Front Physiol       Date:  2018-03-20       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.